Earlier this week, the American Diabetes Association called for
manufacturers of incretin-based therapies to make patient-level data
available from clinical trials for an independent analysis of pancreatic
safety. AstraZeneca
(NYSE: AZN) and Bristol-Myers
Squibb Company (NYSE: BMY) are pleased to see the American Diabetes
Association’s engagement and efforts to facilitate further understanding
of this topic.
AstraZeneca and Bristol-Myers Squibb have been and will continue to work
with health authorities and scientific experts around the world to
closely monitor the use of our GLP-1 receptor agonist and DPP-4
inhibitor through comprehensive surveillance programs to ensure patients
and physicians have a clear understanding of the risk/benefit profile of
these medications.
AstraZeneca and Bristol-Myers Squibb recognize there can be value in
pooling patient level data from trials of agents in a class for the
purpose of an independent meta-analysis of safety sponsored by the
American Diabetes Association. We support the American Diabetes
Association’s initiative to make scientifically valid results of a
pooled analysis of safety data available to the public and scientific
communities through an independent review, and look forward to a
discussion with the American Diabetes Association about the logistics of
its proposal.
AstraZeneca and Bristol-Myers Squibb have an unwavering commitment to
patient safety and the appropriate use of our medicines. We are
committed to communicating accurate and meaningful information about our
sponsored clinical trials in a timely, accurate, balanced and complete
manner, regardless of outcome and with respect for patient
confidentiality.
AstraZeneca/Bristol-Myers Squibb Diabetes Alliance
Dedicated to addressing the global burden of diabetes by advancing
individualized patient care, AstraZeneca and Bristol-Myers Squibb are
working in collaboration to research, develop and commercialize a
versatile portfolio of innovative treatment options for diabetes and
related metabolic disorders that aim to provide treatment effects beyond
glucose control. Find out more about the Alliance and our commitment to
meeting the needs of health care professionals and people with diabetes
at www.astrazeneca.com
or www.bms.com.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
For more information please visit: www.astrazeneca.com
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Media:Bristol-Myers SquibbKen Dominski, 609-252-5251ken.dominski@bms.comorAstraZenecaKirsten Evraire, 302-885-0435kirsten.evraire@astrazeneca.comorInvestors:Bristol-Myers SquibbJohn Elicker, 609-252-4611john.elicker@bms.comorAstraZenecaKarl Hard, 44-20-7604-8123karl.j.hard@astrazeneca.com